Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
MEDICAL EXECUTIVE-POST – TODAY’S NEWSLETTER BRIEFING
***
Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants
“Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily“
A Partner of the Institute of Medical Business Advisors , Inc.
http://www.MedicalBusinessAdvisors.com
SPONSORED BY: Marcinko & Associates, Inc.
***
http://www.MarcinkoAssociates.com
| Daily Update Provided By Staff Reporters Since 2007. How May We Serve You? |
| © Copyright Institute of Medical Business Advisors, Inc. All rights reserved. 2025 |
REFER A COLLEAGUE: MarcinkoAdvisors@outlook.com
SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/
ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z
Your Referral Count -0-
CITE: https://www.r2library.com/Resource
FDA recently approved the first new kind of painkiller since 1998. The drug, called Journavx and made by Vertex Pharmaceuticals, is a non-opioid medication, and the company says it comes with “no evidence of addictive potential.” One downside? At $15.50 per pill, it’s not cheap, and it’s not clear yet how much insurers will cover.
CITE: https://tinyurl.com/2h47urt5
US stocks closed higher on Wednesday as investors weighed President Trump’s latest 25% tariff salvo and digested the Federal Reserve minutes for insight into future policy.
The benchmark S&P 500 (^GSPC) moved up about 0.2%, hitting a fresh record high of 6,144.15, after notching a record on Tuesday as well. The NASDAQ Composite (^IXIC) and the Dow Jones Industrial Average (^DJI) both rose about 0.1%.
Wednesday’s minutes from the Fed’s January meeting revealed most central bank officials supported holding policy at restrictive levels amid concerns about persistent inflation.
CITE: https://tinyurl.com/tj8smmes
Visualize: How private equity tangled banks in a web of debt, from the Financial Times.
COMMENTS APPRECIATED
PLEASE SUBSCRIBE: MarcinkoAdvisors@outlook.com
Thank You
***
***
***
***
EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf
***
Share this:
Filed under: Drugs and Pharma, Ethics, Experts Invited, Financial Planning, Funding Basics, Glossary Terms, Information Technology, Investing, Marcinko Associates | Tagged: asia, DJIA, DOW, FDA, japan, Journavx, Marcinko, NASA, NASDAQ, non-opioid, opioid, S&P 500, Technology, textbooks, TNX, Vertex Pharmaceuticals, VIX |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Leave a comment